Trial Profile
Effect of switching disease-modifying therapy patterns in patients with progressive multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Monoclonal antibodies
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis